Deutsche Bank’s Ultragenyx Pharmaceutical RARE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.51M Sell
71,869
-527,604
-88% -$11.9M ﹤0.01% 1937
2025
Q4
$13.8M Sell
599,473
-946,628
-61% -$31.1M ﹤0.01% 987
2025
Q3
$46.5M Sell
1,546,101
-119,751
-7% -$3.59M 0.02% 640
2025
Q2
$60.6M Sell
1,665,852
-35,641
-2% -$1.28M 0.02% 565
2025
Q1
$61.6M Buy
1,701,493
+8,385
+0.5% +$349K 0.02% 563
2024
Q4
$71.2M Buy
1,693,108
+4,137
+0.2% +$205K 0.03% 552
2024
Q3
$93.8M Sell
1,688,971
-93,369
-5% -$4.76M 0.04% 421
2024
Q2
$73.3M Buy
1,782,340
+575,115
+48% +$24.6M 0.03% 447
2024
Q1
$56.4M Buy
1,207,225
+34,359
+3% +$1.62M 0.03% 525
2023
Q4
$56.1M Buy
1,172,866
+225,134
+24% +$8.73M 0.03% 489
2023
Q3
$33.8M Buy
947,732
+60,001
+7% +$2.38M 0.02% 566
2023
Q2
$41M Sell
887,731
-490
-0.1% -$22.7K 0.02% 560
2023
Q1
$35.6M Buy
888,221
+26,542
+3% +$1.14M 0.02% 607
2022
Q4
$39.9M Buy
861,679
+32,012
+4% +$1.26M 0.02% 576
2022
Q3
$34.4M Buy
829,667
+341,959
+70% +$17.6M 0.02% 612
2022
Q2
$29.1M Buy
487,708
+122,180
+33% +$7.52M 0.02% 684
2022
Q1
$26.5M Sell
365,528
-89,805
-20% -$6.25M 0.01% 761
2021
Q4
$38.3M Buy
455,333
+99,547
+28% +$8.1M 0.02% 664
2021
Q3
$32.1M Sell
355,786
-23,095
-6% -$2.09M 0.02% 737
2021
Q2
$36.1M Sell
378,881
-47,965
-11% -$5M 0.02% 707
2021
Q1
$48.6M Sell
426,846
-33,358
-7% -$4.54M 0.03% 597
2020
Q4
$63.7M Buy
460,204
+28,343
+7% +$3.36M 0.04% 426
2020
Q3
$35.5M Sell
431,861
-49,607
-10% -$4.11M 0.02% 543
2020
Q2
$37.7M Buy
481,468
+6,610
+1% +$438K 0.03% 517
2020
Q1
$21.1M Buy
474,858
+36,989
+8% +$1.92M 0.02% 629
2019
Q4
$18.7M Sell
437,869
-24,508
-5% -$1.01M 0.01% 812
2019
Q3
$19.8M Sell
462,377
-87,618
-16% -$4.76M 0.01% 783
2019
Q2
$34.9M Buy
549,995
+98,699
+22% +$6.28M 0.02% 722
2019
Q1
$31.3M Buy
451,296
+264,422
+141% +$15.1M 0.02% 781
2018
Q4
$8.12M Sell
186,874
-110,679
-37% -$6.05M 0.01% 1442
2018
Q3
$22.7M Sell
297,553
-29,467
-9% -$2.4M 0.01% 1059
2018
Q2
$25.1M Sell
327,020
-37,149
-10% -$2.4M 0.01% 1043
2018
Q1
$18.6M Buy
364,169
+180,492
+98% +$9.09M 0.01% 1166
2017
Q4
$8.52M Sell
183,677
-178,443
-49% -$8.75M 0.01% 1619
2017
Q3
$19.3M Buy
362,120
+154,793
+75% +$9.17M 0.01% 1058
2017
Q2
$12.9M Buy
207,327
+54,237
+35% +$3.27M 0.01% 1218
2017
Q1
$10.4M Sell
153,090
-22,193
-13% -$1.69M 0.01% 1241
2016
Q4
$12.3M Sell
175,283
-38,982
-18% -$2.77M 0.01% 1134
2016
Q3
$15.2M Buy
214,265
+55,799
+35% +$3.56M 0.01% 1051
2016
Q2
$7.75M Sell
158,466
-57,811
-27% -$3.74M 0.01% 1464
2016
Q1
$13.7M Buy
216,277
+50,751
+31% +$3.32M 0.01% 1088
2015
Q4
$18.6M Buy
165,526
+59,173
+56% +$5.92M 0.01% 951
2015
Q3
$10.2M Buy
106,353
+43,835
+70% +$5.02M 0.01% 1270
2015
Q2
$6.4M Buy
62,518
+11,515
+23% +$894K ﹤0.01% 1636
2015
Q1
$3.17M Buy
51,003
+50,968
+145,623% +$2.83M ﹤0.01% 2122
2014
Q4
$1K Sell
35
-2,650
-99% -$121K ﹤0.01% 6085
2014
Q3
$150K Buy
2,685
+1,145
+74% +$57.6K ﹤0.01% 4253
2014
Q2
$69K Sell
1,540
-20,300
-93% -$836K ﹤0.01% 4773
2014
Q1
$1.07M Buy
+21,840
New +$1.12M ﹤0.01% 2819

Other funds holding RARE

Deutsche Bank's RARE Position: Q1 2026 in Review

Deutsche Bank reduced its Ultragenyx Pharmaceutical (RARE) stake by 88% in Q1 2026, selling an estimated $11.9M and leaving 71,869 shares worth $1.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

Deutsche Bank first reported a position in RARE in Q1 2014 and has held it in 49 quarters since. The position peaked at $93.8M in Q3 2024. 295 funds tracked by Wall St. Rank hold RARE as of Q1 2026.

  • Deutsche Bank held 71,869 shares of Ultragenyx Pharmaceutical worth $1.51M as of Q1 2026.
  • Deutsche Bank sold 527,604 Ultragenyx Pharmaceutical shares in Q1 2026, an estimated $11.9M.
  • Ultragenyx Pharmaceutical made up ﹤0.01% of Deutsche Bank's portfolio in Q1 2026, its #1937 holding.
  • Deutsche Bank first reported a position in Ultragenyx Pharmaceutical in Q1 2014 and has held it in 49 quarters since.
  • Deutsche Bank's Ultragenyx Pharmaceutical position peaked at $93.8M in Q3 2024.
  • 295 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.